Eli Lilly Found a New Gear. You Paid For It.
Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb…
Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
Eli Lilly Stock’s Next Climb Runs Through A Pill, Not Just An Injection
The case for more upside rests on its obesity pill, and what changed is not the drug but…
The Signs Before Eli Lilly Stock Surged Were All On The Record
Eli Lilly stock ran on a story that was public and dated long before the price moved, and…
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Management’s plain health care label has slipped out of the lead, and the business now on a separation…
The Real Engine Behind Johnson & Johnson Stock’s Next Climb
While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth…
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
The Catch Hiding In Eli Lilly Stock’s Growth Story
Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
‘We’ve been burned’: Events company fears it ‘might never see money’ owed after ticket firm’s collapse
We need your help now Support from readers like you keeps The Journal open. You are visiting us…